Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia -

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

Masahiro Kizaki (Herausgeber)

Buch | Softcover
193 Seiten
2016 | Softcover reprint of the original 1st ed. 2016
Springer Verlag, Japan
978-4-431-56255-9 (ISBN)
128,39 inkl. MwSt
Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML.

Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.

Professor and Chairman of Department of Hematology in Saitama Medical Center, Saitama Medical University.

1. Identification and Biology of CML Stem Cells.- 2. Molecular Mechanisms of CML Stem Cell Maintenance.- 3. Roles for Signaling Molecules in the Growth and Survival of CML Cells.- 4. Goal of CML Treatment in the Tyrosine Kinase Inhibitor Era.- 5. Biomarkers for Determining the Prognosis of CML.- 6. Updated European Leukemia Net Recommendations for the Management of CML.- 7. Optimal Monitoring of CML Treatment: Molecular and Mutation Analysis.- 8. Recommendations for Management of CML in the Era of Second-Generation TKIs.- 9. Role of New TKIs and Combinations with Interferon-α for the Treatment of CML.- 10. Safety Profiles of First-Line TKIs and Managing Adverse Effects.- 11. Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance.- 12. Discontinuation of Therapy and Treatment-Free Remission in CML.

Erscheinungsdatum
Zusatzinfo 20 Illustrations, color; 6 Illustrations, black and white; VIII, 193 p. 26 illus., 20 illus. in color.
Verlagsort Tokyo
Sprache englisch
Maße 155 x 235 mm
Themenwelt Medizinische Fachgebiete Innere Medizin Hämatologie
Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Medizin / Pharmazie Studium
Schlagworte Chronic Myeloid Leukemia • molecular gnetics • Molecular-targeting thrapy • Stem Cell • TKI • Tyrosine Kinase Inhibitor
ISBN-10 4-431-56255-9 / 4431562559
ISBN-13 978-4-431-56255-9 / 9784431562559
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Hämatologie und Internistische Onkologie

von Dietmar P. Berger; Monika Engelhardt; Justus Duyster

Buch | Softcover (2023)
ecomed-Storck GmbH (Verlag)
129,99